Senses Disorder TRIZ Cases

Topical calreticulin reduces choroidal neovascularization lesions by over 70% without invasive injections.

Avocado oil fraction regenerates cochlear hair cells damaged by ototoxic agents, addressing inadequate sensorineural hearing loss treatments.

Single domain antibodies stabilize the active conformation of metabotropic glutamate receptor subtype 2, resolving orthosteric selectivity conflicts.

A composition combining pepstatin and alginic acid inhibits pepsin in lacrimal fluid.

Density gradient separation isolates endothelial progenitor cells from peripheral blood for targeted culture expansion.

Modified VEGF analogs enhance KDR receptor binding affinity through specific amino acid substitutions, reducing side effects from Flt-1 inhibition.

Spirocyclic amide derivatives combine muscarinic antagonism with beta2 agonism to simplify pulmonary disorder treatment regimens.

Living activated T-cells act as a biological adjuvant to stimulate protective Th1 immunity alongside vaccine antigens.

Localized fluorination on the pyrazolopyrimidine core improves BTK selectivity and reduces off-target side effects.

Dissolving the compound in dimethylformamide or dimethylsulfoxide reduces solvent usage and toxicity risks while enhancing product stability.

Specific binding molecules target Annexin-1 to modulate T cell receptor signaling and skew differentiation toward a less inflammatory Th2 response.

Simplified peptide sequences inhibit neuronal exocytosis to replace botulinum toxins, reducing immunogenic responses and production costs.

Alpha-gal epitope liposomes bind anti-Gal antibodies to recruit macrophages, accelerating tissue repair in diabetic wounds.

Galactomannan and boronic acid copolymer form a stable ocular film, reducing application frequency for dry eye treatment.

Small activating RNA molecules bind non-coding sequences to activate target genes, overcoming the limitation of silencing-only interference technologies.

Aqueous rupatadine fumarate liquid formulation uses cosolvents and pH regulating agents to maintain solubility.

siRNA molecules silence the ORAI1 gene, reducing allergic symptoms and side effects while extending treatment duration.

Targeted pharmaceutical agents modulate enzyme activity to lower neurotoxic peptide levels while preserving physiological functions.

Quinoline derivatives inhibit PI3Kδ activity while preserving other isoforms, resolving discrimination limits of non-specific inhibitors.

Small molecule pyrazolo[1,5-a]pyridine derivatives replace macromolecular inhibitors to achieve potent TNFα modulation with IC50 values under 50 μM.

Vaporization at 170-190°C eliminates pyrolytic byproducts while maintaining rapid onset, resolving bioavailability variability.

Topical lipid compounds accumulate in the retina to treat degenerative disorders without intravitreal injections or systemic side effects.

Azobenzene compounds activate via visible light to stimulate photoreceptors, avoiding UV tissue damage and preserving membrane channel integrity.

Sulfonyl-quinoline ligands resolve potency and selectivity trade-offs by optimizing substituent positions on the quinoline core.

Culturing human corneal epithelial cells on an amnion substrate with mesenchymal stem cell feeders stabilizes sheet quality and reduces rejection rates.

Topical levodopa compositions with antioxidants elevate intraocular dopamine to inhibit visual disorders without systemic side effects.

Benzyl benzoate formulation delivers latanoprost via intraocular injection to reduce administration frequency and improve patient compliance.

Topical adrenergic agents modify ocular physiology to enhance drug penetration into the posterior segment.

Enzyme-treated molding contact lenses alter corneal curvature for vision correction without surgical incisions.

Replacing sodium azide with diphenylphosphoryl azide eliminates toxicity and cost barriers while optimizing orotic acid ratios for enhanced bioavailability.

A biphenyl sulfonamide compound blocks angiotensin II and endothelin-1 receptors simultaneously.

BRD-4780 binds TMED9 to release mutant proteins from the early secretory pathway, resolving toxic accumulation in kidney and retinal diseases.

Testicle-derived mesenchymal stem cells bypass bone marrow extraction discomfort while maintaining therapeutic efficacy for canine and feline diseases.

Modified molecular structures cross the blood-brain barrier to deliver effective P2X7 receptor antagonism.

Specific tear protein markers enable accurate dry eye diagnosis while lacritin restores underlying physiological function.

Ultrasonic cavitation breaks adipose tissue and lyses mature cells to isolate viable stem cells without enzymatic treatment.

N-oxide pyrazine derivatives inhibit GSK3β to reduce tau hyperphosphorylation and enhance neuronal survival in neurodegenerative diseases.

An ab interno drainage implant reduces intraocular pressure by diverting aqueous humor to the uveoscleral pathway, improving patient compliance.

Engineered IGFBP-3 derivatives resist proteolytic cleavage, extending half-life and efficacy while reducing side effects.

C-7 substituted rapamycin analogs selectively inhibit mTORC1 while sparing mTORC2 to reduce metabolic side effects.

Segmenting large genes into two overlapping AAV vectors overcomes packaging limits and ensures transcript fidelity.

Heteroaryl compounds replace costly biologics to reduce manufacturing expenses and injection frequency.

Cytokine-carrier conjugates induce neutralizing antibodies to desensitize patients.

Novel multifunctional radical quenchers augment ATP production and remove reactive oxygen species.

Combining piperidino-dihydrothienopyrimidine sulfoxides with celecoxib reduces PDE4-mediated side effects, enabling higher dosages for COPD treatment.